Kardigan (NASDAQ:KARD – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.
A number of other equities research analysts also recently weighed in on KARD. Cantor Fitzgerald initiated coverage on Kardigan in a research report on Thursday, October 29th. They set an “overweight” rating and a $50.00 price target on the stock. JPMorgan Chase & Co. cut their price objective on Kardigan from $51.00 to $46.00 and set an “overweight” rating for the company in a report on Tuesday, August 25th. Leerink Partners cut their price objective on Kardigan from $37.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, November 13th. Robert W. Baird began coverage on Kardigan in a research report on Wednesday, October 21st. They set an “outperform” rating and a $43.00 price objective on the stock. Finally, HC Wainwright began coverage on Kardigan in a report on Wednesday, November 4th. They set a “buy” rating and a $42.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.00.
Check Out Our Latest Report on KARD
Kardigan Stock Performance
Kardigan (NASDAQ:KARD – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.16. As a group, equities analysts forecast that Kardigan will post -3.41 earnings per share for the current year.
Institutional Trading of Kardigan
Several hedge funds have recently added to or reduced their stakes in KARD. Russell Investments Group Ltd. purchased a new position in shares of Kardigan in the third quarter worth about $31,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Kardigan in the 3rd quarter valued at about $47,000. Legal & General Group Plc purchased a new stake in Kardigan during the 2nd quarter valued at about $119,000. New York State Common Retirement Fund purchased a new stake in Kardigan during the 3rd quarter valued at about $145,000. Finally, Squarepoint Ops LLC purchased a new stake in Kardigan during the 2nd quarter valued at about $247,000.
Kardigan Company Profile
Kardigan is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. Its work centers on advancing therapeutic candidates intended to address heart and vascular conditions. The company’s activities include research and development of a pipeline of cardiovascular drug candidates. Kardigan was launched as a biotechnology company in 2024; detailed information about its commercial products and geographic operations is limited.
Further Reading
- Five stocks we like better than Kardigan
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Kardigan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kardigan and related companies with MarketBeat.com's FREE daily email newsletter.
